Prerpints.org logo
Preprint
Review

New Therapeutics for Heart Failure Worsening: Focus on Vericiguat

Altmetrics

Downloads

117

Views

52

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

01 July 2024

Posted:

02 July 2024

You are already at the latest version

Alerts
Abstract
Heart failure (HF) is a syndrome characterized by signs and symptoms resulting from structural or functional cardiac abnormalities, confirmed by elevated natriuretic peptides or evidence of congestion. HF patients are classified according to left ventricular ejection fraction (LVEF). Worsening HF (WHF) is associated with increased short- and long-term mortality, re-hospitalization, and healthcare costs. Standard treatment of HF includes angioten-sin-converting enzyme inhibitors, angiotensin receptor-neprilysin inhibitors, mineralocorti-coid-receptor antagonists, beta-blockers, and sodium-glucose co-transporter 2 inhibitors. To manage systolic HF by reducing mortality and hospitalizations in patients experiencing WHF, treatment with vericiguat, a direct stimulator of soluble guanylate cyclase (sGC), is indicated. This drug acts by stimulating sGC enzymes, part of the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) signaling pathway, regulating the cardiovascular system by catalyzing cGMP synthesis in response to NO. cGMP acts as a second messenger, triggering various cellular effects. Deficiencies in cGMP production, often due to low NO availability, are implicated in cardiovascular diseases. Vericiguat stimulates sGC directly, bypassing the need for a functional NO-sGC-cGMP axis, thus preventing myocardial and vascular dysfunction associated with de-creased sGC activity in heart failure. Approved by the FDA in 2021, vericiguat administration should be considered, in addition to the four pillars of HFrEF therapy, in symptomatic patients with LVEF < 45% following a worsening event. Cardiac rehabilitation represents an ideal setting where there is more time to implement therapy with vericiguat and incorporate a greater num-ber of medications for the management of these patients. This review covers vericiguat's metab-olism, molecular mechanisms, and drug-drug interactions.
Keywords: 
Subject: Medicine and Pharmacology  -   Cardiac and Cardiovascular Systems

1. Introduction to Heart Failure (HF) and to Worsening HF (WHF)

The guidelines from the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Failure Society of America (HFSA) define HF as “a clinical syndrome marked by symptoms and signs arising from structural heart disease, heightened filling pressures, or increased levels of natriuretic peptides”. This definition specifically excludes individuals with asymptomatic structural heart disease who are deemed to be at risk for HF. According to the Universal Definition, HF is characterized by a clinical syndrome featuring signs and/or symptoms stemming from structural and/or functional cardiac abnormalities, which are corroborated by elevated natriuretic peptides and/or objective evidence of pulmonary or systemic congestion [1,2]. Patients with HF are categorized based on left ventricular ejection fraction (LVEF) into those with reduced EF (HFrEF, EF ≤ 40%), mildly reduced EF (HFmrEF, EF 41–49%), preserved EF (HFpEF, EF ≥ 50%), and improved EF (HFimpEF, baseline EF ≤ 40%, a ≥ 10-point increase in EF, and a second EF > 40%) [3].
The clinical progression of heart failure (HF) is characterized by episodes of deteriorating symptoms and signs (Figure 1)
These instances of worsening HF (WHF) are followed by an elevated risk of hospitalizations and mortality, imposing a significant strain on the healthcare system due to their frequency, urgency, and prognostic implications. WHF denotes the gradual decline in the heart capacity to efficiently pump blood, resulting in insufficient delivery of oxygen and nutrients to satisfy body demands. This deterioration typically presents with symptoms such as dyspnea, fatigue, fluid retention, and diminished exercise tolerance, and it can manifest gradually over time or abruptly during acute exacerbations [5].
The pathophysiology underlying WHF involves a decline in the heart pumping function. Common culprits include chronic conditions like coronary artery disease, hypertension, and cardiomyopathies. As the heart strength diminishes, it struggles to expel blood effectively, leading to fluid accumulation in the lungs and peripheral tissues. Neurohormonal systems, such as the renin-angiotensin-aldosterone system and the sympathetic nervous system, often become activated in an effort to compensate, but these mechanisms can contribute to further cardiac damage and worsening function. Additionally, inflammatory processes and structural alterations in the heart may also contribute to the progression of heart failure. [5].
The management of WHF has traditionally relied on hospital-based care. However, the growing prevalence of HF and its associated costs on healthcare systems have prompted the development of alternative approaches to prolonged hospitalizations [6]. Guidelines advocate for the use of Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin receptor-neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonists, beta-blockers, and Sodium-glucose co-transporter 2 (SGLT-2) inhibitors to mitigate the risk of HF hospitalizations and mortality. Recent analyses also demonstrate the effectiveness of guideline-recommended medical therapy (GRMT) in preventing outpatient WHF events, such as emergency visits requiring IV diuretic administration and outpatient visits requiring diuretic dose intensification [7].
Preprints 110911 g002
Figure 2. Guidelines for pharmacological intervention at every phase of heart failure. Recommendations for pharmacological therapy across the spectrum of HF stages, from risk prevention to advanced HF (stages A to D), are delineated below. Each treatment is color-coded based on the class of recommendation and level of evidence as outlined in HF guidelines. ACEI (angiotensin-converting enzyme inhibitor), ARB (angiotensin receptor blocker), ARNI (angiotensin receptor–neprilysin inhibitor), CKD (chronic kidney disease), GDMT (guideline-directed medical therapy), HFmrEF (HF with mildly reduced ejection fraction), HFpEF (HF with preserved ejection fraction), HFrEF (HF with reduced ejection fraction), LVEF (left ventricular ejection fraction), MCS (mechanical circulatory support), MRA (mineralocorticoid receptor antagonist), SGLT2 (sodium–glucose cotransporter 2), uACR (urine albumin-to-creatinine ratio). Adapted from Bozkurt, 2024 [4]
Figure 2. Guidelines for pharmacological intervention at every phase of heart failure. Recommendations for pharmacological therapy across the spectrum of HF stages, from risk prevention to advanced HF (stages A to D), are delineated below. Each treatment is color-coded based on the class of recommendation and level of evidence as outlined in HF guidelines. ACEI (angiotensin-converting enzyme inhibitor), ARB (angiotensin receptor blocker), ARNI (angiotensin receptor–neprilysin inhibitor), CKD (chronic kidney disease), GDMT (guideline-directed medical therapy), HFmrEF (HF with mildly reduced ejection fraction), HFpEF (HF with preserved ejection fraction), HFrEF (HF with reduced ejection fraction), LVEF (left ventricular ejection fraction), MCS (mechanical circulatory support), MRA (mineralocorticoid receptor antagonist), SGLT2 (sodium–glucose cotransporter 2), uACR (urine albumin-to-creatinine ratio). Adapted from Bozkurt, 2024 [4]
Preprints 110911 g002
New data emerged from the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, which enrolled patients with LVEF <45%, New York Heart Association (NYHA) Classification class II–IV, elevated natriuretic peptide concentrations, and WHF. WHF was defined as an HF hospitalization within 6 months before randomization or an episode of decompensation with outpatient treatment using IV furosemide 3 months before randomization [8,9]. The study identified a high-risk group where the annual event rate of cardiovascular death or heart failure (HF) hospitalizations was 37.8 events per 100 patient-years for those on placebo and 33.6 events per 100 patient-years for those on vericiguat. The 10% relative risk reduction of the primary endpoint (HR 0.90, 95% CI 0.82–0.98) corresponded to a 3.7 absolute risk reduction, which was similar in magnitude to that reported by previous trials [9,10]. The benefit of Vericiguat did not significantly vary across different levels of risk in WHF and across the range of times from WHF to randomization. Based on these results, Vericiguat administration should be considered, in addition to the four pillars of HFrEF therapy, in symptomatic patients with LVEF <45% following a WHF event [11,12]. Furthermore, exercise rehabilitation appears to decrease the likelihood of subsequent HF events in older, frail patients admitted for decompensated HF, particularly in individuals who adhere closely to the exercise program [12,13,14].In addition, the new updated 2024 Cochrane review, which provided additional evidence from 16 randomized trials, supported the conclusions of the previous 2018 version , i.e., that exercise-based cardiac rehabilitation (ExCR) likely reduces the risk of all-cause hospital admissions and heart failure-related hospital admissions, and may result in important improvements in health-related quality of life (HRQoL) [15].

2. Vericiguat

Vericiguat, commercial name Verquvo/BAY 1021189, a compound with a molecular weight of 426.4, is a 5-fluoro-1H-pyrazolo [3,4-b]pyridine [IUPAC name: methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate C19H16F2N8O2 Figure 3]. In this molecule, the amino hydrogen at position 1 has been replaced by a 2-fluorobenzyl group, and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group [16]. Vericiguat was approved by FDA (First approved January 19, 2021 [17] by EMA (16 July 2021) [18], and by the Pharmaceuticals and Medical Device Agency in Japan in 2021 [19] for: HF with reduced ejection fraction. Similar drugs: Dapagliflozin, Riociguat, Sacubitril/ Valsartan
Vericiguat is characterized as a weakly basic drug with low water solubility and high intestinal permeability, classified as Class II according to the Biopharmaceutics Classification System [20].
Vericiguat undergoes primarily glucuronidation, facilitated by uridine diphosphate-glucuronosyltransferase (UGT 1A9 and UGT 1A1), leading to the formation of N-glucuronide M-1, which lacks pharmacological activity against sGC. A minor fraction of the drug (<5%) undergoes metabolism via the P450 (CYP450) clearance pathway [20]. [Figure 4]. While sex and body weight are significant covariates in vericiguat’s volume of distribution, age, ethnicity, bilirubin, estimated glomerular filtration rate (eGFR), and albumin concentration do not affect the pharmacokinetics of vericiguat [21,22].
Following the oral administration of radiolabeled vericiguat, approximately 53% of the administered radioactivity was recovered in the urine and 45% in the feces. A human mass balance study revealed that the urine portion comprised approximately 40.8% N-glucuronide metabolite, 7.7% other metabolites, and 9% unchanged parent drug, while virtually the entire portion recovered in the feces consisted of unchanged vericiguat. Vericiguat is a low-clearance drug, with an observed plasma clearance of 1.6 L/h in healthy volunteers and 1.3 L/h in patients with systolic heart failure. The half-life of vericiguat is 30 hours in patients with heart failure [23].
The adverse side effects of vericiguat primarily include symptomatic hypotension due to vasorelaxation, syncope, and anemia. Changes in vasoactive hormones for cGMP, plasma renin activity, noradrenaline, as well as a decrease in creatinine, urea, and uric acid levels have also been observed.
Vericiguat stimulates directly soluble guanylate cyclase (sGC) enzyme [24] that amplifies the effects of nitric oxide (NO) [25]
In heart failure, a reduced NO availability can be observed, due to a reduced eNOS actvity, secondary to inflammation and increase in TNFα production. [26]. Keeping sufficient levels of NO is essential to maintain normal cardiac contractility and vascular tone [27], as it act by binding the heme-containing domain of the sGC enzyme and directly stimulates the production of cGMP which, in turn, exert several effects on vascular cells, regulating endothelial permeability, cell growth, vasomotor tone, and interactions with circulating blood cells [28]. Along with a direct stimulation of sGC, vericiguat also increases the positive effects of NO, by stabilizing the nitrosyl-heme complex [29], thus resulting in the restoration of the NO-sGC-cGMP pathway even in low-NO levels microenvironment.
Below, we will describe in detail the components of the NO-sGC-cGMP pathway and the synergistic effect of vericiguat.

2.1. Nitric Oxide (NO)

Nitric oxide (NO) is an endogenous vasodilator produced by various cells in the body by a family of enzymes called nitric oxide synthases [NOS, NOS III, and NOS3) by the oxidation of L-arginine (L-Arg) to L-citrulline [Figure 5].
Nitric oxide synthase is present in three isoforms, known as neuronal (nNOS or NOS1), inducible (iNOS or NOS2), and endothelial (eNOS or NOS3). Both nNOS and eNOS are calcium-dependent enzymes that are constitutively expressed in various cells throughout the body, producing picomolar or nanomolar amounts of NO. iNOS, also found in multiple cell types, is induced in immunological or inflammatory conditions, typically triggered by IL1β, TNF, and LPS, resulting in the generation of micromolar or millimolar levels of NO. Nitrate can be converted to nitrite by nitrate reductase produced by oral cavity bacteria. Nitrite, in turn, is reduced to NO by nitrite reductases, which are oxygen-independent enzymes such as xanthine oxidoreductase, deoxyhemoglobin, and deoxymyoglobin. NO generated by nitrite reductase induces vasodilation in the cardiovascular system, thereby promoting cell survival by increasing blood flow even under hypoxic conditions. [30]. The half-life of NO is very brief (approximately 2 milliseconds in the blood and 2 seconds in the tissues). Nevertheless, its steady-state concentration is a crucial factor in determining its biological function. Different cellular targets respond to varying concentrations of NO. For instance, processes mediated by cyclic guanosine monophosphate (cGMP) are activated when NO concentration is below 1–30 nM, while stabilization of hypoxia-inducible factor-1α (HIF-1α) happens at NO concentrations ranging between 100 and 300 nM. NO can be viewed as both an autocrine and paracrine signaling molecule, with its lifespan and diffusion gradients constrained by scavenging reactions involving hemoglobin, myoglobin, and other radicals. Nevertheless, NO can be stabilized in the bloodstream and tissues through oxidation to nitrate and nitrite. These compounds can be regarded as endocrine molecules that are circulated in the blood, accumulate in tissues, and possess the potential to be converted back to NO under both physiological and pathological conditions [30].
The identification and characterization of the complex machinery responsible for NO generation by endothelial cells, along with its role in endothelium-dependent vascular relaxation in 1990 by Salvador Moncada [31], represent a significant milestone in defining the fundamental mechanisms regulating vascular physiology and regional blood flow adjustment. The evidence supporting the pivotal role of NO released by endothelial cells in the intrinsic relaxation of vascular smooth muscle cells, coupled with potent anti-platelet action, has been instrumental in understanding the pathophysiology of relevant disease states such as atherothrombosis, vascular injury, and heart failure [32]. Furthermore, the recognition of NO/cGMP signaling’s critical role in cardiac contraction and relaxation has contributed to understanding the intricate processes underlying myocardial dysfunction, encompassing both reduced and preserved ejection fraction [33,34].
In blood vessels, NO is continuously generated from L-arginine by the enzyme endothelial NO synthase (eNOS), which is the most abundant isoform of NOS (Figure 4). The continuous activation of eNOS is due to endothelial cells responding to forces induced by the streaming blood, such as shear stress, which triggers the phosphorylation of eNOS by the Ser/Thr protein kinase PKB/Akt. Additionally, activation of endothelial cells by hormones or biogenic amines acting on G-protein-coupled receptors (GPCRs) increases endothelial free Ca2+ levels. This signal stimulates eNOS activity in a Ca2+-calmodulin-dependent manner and contributes to the physiological adaptation controlling regional blood flow in tissues.
Among other significant effects of NO is the vasodilation that occurs primarily through a reduction in cytosolic Ca2+ levels following the activation of soluble guanylyl cyclase (sGC) in smooth muscle. Active sGC converts guanosine-5′-triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), which binds to and activates protein kinase G (PKG). PKG I phosphorylates several proteins involved in cellular Ca2+ homeostasis, including 1,4,5-inositoltrisphosphate (IP3) receptor-associated cGMP kinase substrate (IRAG), blocking IP3-evoked Ca2+ release from the sarcoplasmic reticulum by inhibiting the IP3-receptor I in its membrane. Furthermore, PKG I phosphorylates the large-conductance calcium-activated potassium channels (BKCa K+-channels), increasing their open probability, promoting potassium outflow and hyperpolarization, thereby reducing the effect of depolarizing signals.
Finally, NO actives the sarcoplasmic reticulum ATPase (SERCA), inducing sequestration from the cytosol into the SR, in a cGMP-independent manner through direct NO (and superoxide)-induced reversible S-glutathiolation at Cys674 of SERCA.

2.2. NO-sGC Pathway

Briefly, in vivo, the effects of NO are mediated through both cGMP-dependent and cGMP-independent pathways. In the cGMP-dependent pathway, NO signals are translated into increased cGMP levels by activating soluble guanylate cyclase. Elevated cellular cGMP, in turn, stimulates various protein kinases within the cell. These kinases then inhibit platelet aggregation, induce smooth muscle relaxation, and modulate cell growth and differentiation [35].
In the cGMP-independent pathway, the NO signal induces modifications to protein structure through S-nitrosylation, S-glutathionylation, and tyrosine nitration. These alterations in cellular protein conformation result in changes in functional activity. The NO–sGC–cGMP pathway is a critical signaling mechanism involved in cardiovascular, cardio-pulmonary, and cardiorenal regulation. sGC (soluble guanylate cyclase) comprises α- and β-subunits with a NO-binding structure. NO after diffusion in the cytosol across cell membranes binds to cytosolic sGC, inducing a conformational change in the enzyme and activating its catalytic site, which converts guanosine triphosphate to cGMP. cGMP then binds to and activates cGMP-activated protein kinases, cGMP-regulated ion channels, and cGMP-regulated phosphodiesterases (PDEs). This pathway plays a crucial role in regulating vascular tone and maintaining tissue homeostasis through various mechanisms, including anti-fibrotic and anti-inflammatory effects [35,36].
Dysregulation of the NO–sGC–cGMP signaling pathway can occur through oxidative stress, which alters the redox state of sGC, leading to the formation of oxidized and haem-free sGC (apo-sGC), rendering it unresponsive to NO. Endothelial dysfunction can also impair NO production, resulting in decreased NO bioavailability and reduced tissue cGMP levels. Additionally, other factors contributing to impaired NO–sGC–cGMP signaling include decreased levels of L-arginine due to arginase activity, limited availability of L-arginine, downregulation of nitric oxide synthase (NOS) in the vascular endothelium, NO inactivation by superoxide anion, elevated plasma concentrations of the endogenous NOS inhibitor ADMA (Asymmetric dimethylarginine), disrupted sGC transcription, and reduced stability of sGC mRNA. These dysfunctions can lead to various cardiovascular, cardiopulmonary, and cardiorenal diseases, such as pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension [35,36,37]. Acute inflammation can also have an effect on NO levels, as increased concentration of TNFα can reduce eNOS activity [26].

2.3. Vericiguat Molecular Mechanism

As reported above, under physiological conditions, the vascular endothelium produces NO, which in turn stimulates the sGC-mediated synthesis of cyclic guanosine monophosphate (cGMP) [38]. The endocardial endothelium, responsive to NO, modulates contractility and diastolic function by elevating cGMP levels [38]. cGMP activation leads to the activation of protein kinase G (PKG), initiating downstream pathways that promote vasodilation, reduce inflammation and fibrosis, inhibit hypertrophy, and diminish cardiac remodeling [39]. Vericiguat’s significance in heart failure (HF) treatment stems from the hindrance of NO-dependent intracellular cGMP generation due to ongoing inflammation, oxidative stress, and endothelial dysfunction, which lower NO levels [40] (Figure 6).
This enzyme is crucial for cyclic guanosine monophosphate (cGMP) generation in cardiac and vascular tissues, serving as a messenger to facilitate cardiac and vasorelaxation via phosphokinase G. Studies have revealed cGMP deficiency in both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) [41]. Vericiguat additionally stabilizes nitric oxide at its binding site, enhancing sGC sensitivity to nitric oxide [42].
cGMP is also modulated by additional signaling pathways. Natriuretic peptides (NPs), including atrial natriuretic peptide and B-type natriuretic peptide, augment cGMP levels by activating membrane-bound guanylate cyclase, particularly guanylate cyclase, pGC [43].

2.4. Drug-Drug Interactions

The administration of omeprazole, a proton pump inhibitor (PPI) used in acid reflux treatment, has been shown to decrease the absorption of vericiguat. However, drug-drug interaction studies suggest that vericiguat is suitable for managing patients with heart failure and multiple comorbidities requiring multiple medications. It’s important to note that if a patient is taking a long-acting nitrate, guanylate cyclase stimulator, or phosphodiesterase-5 (PDE5) inhibitor, vericiguat should be avoided to prevent syncope and hypotension. Additionally, patients with severe anemia should avoid vericiguat due to concerns that the drug may decrease hemoglobin levels [20].

2.5. Implementation of a Personalized Therapy

Guideline-directed medical therapy (GDMT) reduces cardiovascular mortality and morbidity, and enhances quality of life for patients with HF and HFrEF. However, despite the recent advancements in pharmacotherapy for WHF, as described above, effectively implementing GDMT in clinical practice remains challenging [44]. Besides clinical inertia, clinical conditions such as hypotension, impaired renal function, hyperkalemia, and polypharmacy—which contraindicate therapy and/or are associated with low tolerability—may partially explain the poor implementation of GDMT frequently observed in HFrEF patients. At the patient level, non-adherence to cardiovascular pharmacotherapy is the primary barrier. Approximately 30–75% of older adults do not take their medications as prescribed, 50% of prescriptions are known to be taken incorrectly, and 33–69% of drug-related hospital admissions are due to patients not following their medication regimens. Non-adherence is exacerbated by factors such as polypharmacy, multimorbidity, physical or cognitive impairment, poor patient education, and the cost and complexity of treatment. This non-adherence is associated with poor quality of life (QoL), increased hospitalizations, mortality, and higher medical costs. Therefore, assessing adherence should be a routine part of patient care [45].
Importantly, a recent real-world study found that despite participants being older than those in clinical trials, adherence to and persistence with vericiguat were satisfactory across all age groups. Starting vericiguat resulted in an intensification of concomitant GDMT, although a better understanding of barriers to up-titration of vericiguat and the implementation of other GDMT, particularly for women and elderly patients, require further evidence [46]. Monitoring patient’s adherence requires significant time and resource allocation. Additionally, vericiguat necessitates a titration regimen, which includes two up-titration visits spaced two weeks apart to achieve the maximum dose. This process results in a total titration period of 28 days to increase the dosage from 2.5 mg to 10 mg. Cardiac rehabilitation (CR) - a comprehensive disease management program strongly recommended by HF guidelines [47] - represents an ideal setting where there is more time to implement therapy and incorporate a greater number of essential medications for the management of these patients.

3. Conclusions

Vericiguat is a critical treatment option for high-risk patients with HFrEF who are already receiving guideline-directed medical therapy and have recently experienced worsening heart failure. Targeting cGMP pathway presents a distinctive mechanism of action, potentially enhancing clinical outcomes for patients with HFrEF.
As awareness of the clinical and prognostic significance of WHF grows, vericiguat effectively fills an important therapeutic gap by reducing the incidence of cardiovascular death and WHF in high-risk HFrEF patients. The possibility to expand the use of vericiguat to a broader range of patients is presently investigated by the VICTOR study, a phase III randomized, placebo-controlled clinical trial, on the effectiveness and safety of the sGC stimulator Vericiguat/MK-1242 in adults diagnosed with HFrEF who have not been hospitalized for heart failure recently or required outpatient intravenous diuretics. [47].
Ongoing research and clinical insights will continue to clarify the role of vericiguat in managing HF and its potential to alleviate the healthcare burden associated with this condition. Through continued study and development, vericiguat holds promise to transform the treatment approach for HF, offering new possibilities for enhanced outcomes and quality of life for patients globally.

Author Contributions

“Conceptualization, P.R.; G.R. M.V. C.T. and S.B..; methodology, L.V. and F.M..; software, F.M.; writing—original draft preparation, P.R.; L.V..; writing—review and editing, G.R. M.V. C.T. and S.B..; supervision, G.R. M.V.; and S.B..; funding acquisition, P.R.; S.B. All authors have read and agreed to the published version of the manuscript.”

Funding

The work was supported by current research funding from the Ministry of Health (Ricerca Corrente), Rome, Italy. PR and SB was supported by Competitive Funding for University Research Projects [Finanziamento competitivo di progetti di ricerca di ateneo (FIN/RIC)] San Raffaele University; Department of Human Sciences and Promotion of the Quality of Life, Via di Val Cannuta 247, 00166 Rome,

Institutional Review Board Statement

“Not applicable” for studies not involving humans or animals.

Informed Consent Statement

“Not applicable” for studies not involving humans or animals.

Data Availability Statement

.Not applicable

Conflicts of Interest

The authors declare no conflicts of interest

References

  1. Abovich, A.; Matasic, D. S.; Cardoso, R.; Ndumele, C. E.; Blumenthal, R. S.; Blankstein, R.; Gulati, M. The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention. American Journal of Preventive Cardiology 2023, 15, 100527. [Google Scholar] [CrossRef] [PubMed]
  2. Riccardi, M.; Sammartino, A. M.; Piepoli, M.; Adamo, M.; Pagnesi, M.; Rosano, G.; Metra, M.; Von Haehling, S.; Tomasoni, D. Heart Failure: An Update from the Last Years and a Look at the near Future. ESC Heart Failure 2022, 9(6), 3667–3693. [Google Scholar] [CrossRef] [PubMed]
  3. Members, A. F.; McDonagh, T. A.; Metra, M.; Adamo, M.; Gardner, R. S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; Cleland, J. G. F.; Coats, A. J. S.; Crespo-Leiro, M. G.; Farmakis, D.; Gilard, M.; Heymans, S.; Hoes, A. W.; Jaarsma, T.; Jankowska, E. A.; Lainscak, M.; Lam, C. S. P.; Lyon, A. R.; McMurray, J. J. V.; Mebazaa, A.; Mindham, R.; Muneretto, C.; Francesco Piepoli, M.; Price, S.; Rosano, G. M. C.; Ruschitzka, F.; Kathrine Skibelund, A.; Group, E. S. D. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure 2022, 24(1), 4–131. [Google Scholar] [CrossRef] [PubMed]
  4. Bozkurt, B. Contemporary Pharmacological Treatment and Management of Heart Failure. Nat Rev Cardiol 2024. [CrossRef] [PubMed]
  5. Metra, M.; Tomasoni, D.; Adamo, M.; Bayes-Genis, A.; Filippatos, G.; Abdelhamid, M.; Adamopoulos, S.; Anker, S. D.; Antohi, L.; Böhm, M.; Braunschweig, F.; Gal, T. B.; Butler, J.; Cleland, J. G. F.; Cohen-Solal, A.; Damman, K.; Gustafsson, F.; Hill, L.; Jankowska, E. A.; Lainscak, M.; Lund, L. H.; McDonagh, T.; Mebazaa, A.; Moura, B.; Mullens, W.; Piepoli, M.; Ponikowski, P.; Rakisheva, A.; Ristic, A.; Savarese, G.; Seferovic, P.; Sharma, R.; Tocchetti, C. G.; Yilmaz, M. B.; Vitale, C.; Volterrani, M.; Von Haehling, S.; Chioncel, O.; Coats, A. J. S.; Rosano, G. Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of Cardiology. European J of Heart Fail 2023, 25(6), 776–791. [Google Scholar] [CrossRef]
  6. Savarese, G.; Becher, P. M.; Lund, L. H.; Seferovic, P.; Rosano, G. M. C.; Coats, A. J. S. Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology. Cardiovascular Research 2022, 118(17), 3272–3287. [Google Scholar] [CrossRef] [PubMed]
  7. Solomon Scott D.; McMurray John J.V.; Claggett Brian; de Boer Rudolf A.; DeMets David; Hernandez Adrian F.; Inzucchi Silvio E.; Kosiborod Mikhail N.; Lam Carolyn S.P.; Martinez Felipe; Shah Sanjiv J.; Desai Akshay S.; Jhund Pardeep S.; Belohlavek Jan; Chiang Chern-En; Borleffs C. Jan Willem; Comin-Colet Josep; Dobreanu Dan; Drozdz Jaroslaw; Fang James C.; Alcocer-Gamba Marco Antonio; Al Habeeb Waleed; Han Yaling; Cabrera Honorio Jose Walter; Janssens Stefan P.; Katova Tzvetana; Kitakaze Masafumi; Merkely Béla; O’Meara Eileen; Saraiva Jose Francisco Kerr; Tereshchenko Sergey N.; Thierer Jorge; Vaduganathan Muthiah; Vardeny Orly; Verma Subodh; Pham Vinh Nguyen; Wilderäng Ulrica; Zaozerska Natalia; Bachus Erasmus; Lindholm Daniel; Petersson Magnus; Langkilde Anna Maria. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine 2022, 387 (12), 1089–1098. [CrossRef]
  8. Butler, J.; Usman, M. S.; Anstrom, K. J.; Blaustein, R. O.; Bonaca, M. P.; Ezekowitz, J. A.; Freitas, C.; Lam, C. S. P.; Lewis, E. F.; Lindenfeld, J.; McMullan, C. J.; Mentz, R. J.; O’Connor, C.; Rosano, G. M. C.; Saldarriaga, C. I.; Senni, M.; Udelson, J.; Voors, A. A.; Zannad, F. Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction across the Risk Spectrum. European Journal of Heart Failure 2022, 24(11), 2029–2036. [Google Scholar] [CrossRef] [PubMed]
  9. Armstrong Paul, W. ; Pieske Burkert; Anstrom Kevin J.; Ezekowitz Justin; Hernandez Adrian F.; Butler Javed; Lam Carolyn S.P.; Ponikowski Piotr; Voors Adriaan A.; Jia Gang; McNulty Steven E.; Patel Mahesh J.; Roessig Lothar; Koglin Joerg; O’Connor Christopher M. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine 2020, 382 (20), 1883–1893. [CrossRef]
  10. Butler, J.; Anstrom, K. J.; Armstrong, P. W. ; For the VICTORIA Study Group. Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. Circulation 2020, 142 (8), 717–719. [CrossRef]
  11. Rao, V. N.; Diez, J.; Gustafsson, F.; Mentz, R. J.; Senni, M.; Jankowska, E. A.; Bauersachs, J. Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. Journal of Cardiac Failure 2023, 29(3), 389–402. [Google Scholar] [CrossRef] [PubMed]
  12. Tomasoni, D.; Adamo, M.; Bozkurt, B.; Heidenreich, P.; McDonagh, T.; Rosano, G. M. C.; Virani, S. A.; Zieroth, S.; Metra, M. Aiming at Harmony. Comparing and Contrasting International HFrEF Guidelines. European Heart Journal Supplements 2022, 24 (Supplement_L), L20–L28. [CrossRef]
  13. Nelson, M. B.; Gilbert, O. N.; Duncan, P. W.; Kitzman, D. W.; Reeves, G. R.; Whellan, D. J.; Mentz, R. J.; Chen, H.; Hewston, L. A.; Taylor, K. M.; Pastva, A. M. Intervention Adherence in REHAB-HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events. J Am Heart Assoc 2022, 11(11), e024246. [Google Scholar] [CrossRef] [PubMed]
  14. Pandey, A.; Kitzman, D. W.; Nelson, M. B.; Pastva, A. M.; Duncan, P.; Whellan, D. J.; Mentz, R. J.; Chen, H.; Upadhya, B.; Reeves, G. R. Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2023, 8(2), 167. [Google Scholar] [CrossRef] [PubMed]
  15. Molloy, C.; Long, L.; Mordi, I. R.; Bridges, C.; Sagar, V. A.; Davies, E. J.; Coats, A. J.; Dalal, H.; Rees, K.; Singh, S. J.; Taylor, R. S. Exercise-Based Cardiac Rehabilitation for Adults with Heart Failure. Cochrane Database of Systematic Reviews 2024, 2024 (3). [CrossRef]
  16. PubChem. Vericiguat. https://pubchem.ncbi.nlm.nih.gov/compound/54674461 (accessed 2024-06-3).
  17. Sheikhi, N.; Bahraminejad, M.; Saeedi, M.; Mirfazli, S. S. A Review: FDA-Approved Fluorine-Containing Small Molecules from 2015 to 2022. European Journal of Medicinal Chemistry 2023, 260, 115758. [Google Scholar] [CrossRef] [PubMed]
  18. Markham, A.; Duggan, S. Vericiguat: First Approval. Drugs 2021, 81(6), 721–726. [Google Scholar] [CrossRef] [PubMed]
  19. Shiba, M.; Kato, T.; Morimoto, T.; Yaku, H.; Inuzuka, Y.; Tamaki, Y.; Ozasa, N.; Seko, Y.; Yamamoto, E.; Yoshikawa, Y.; Kitai, T.; Yamashita, Y.; Iguchi, M.; Nagao, K.; Kawase, Y.; Morinaga, T.; Toyofuku, M.; Furukawa, Y.; Ando, K.; Kadota, K.; Sato, Y.; Kuwahara, K.; Kimura, T. Heterogeneity in Characteristics and Outcomes of Patients Who Met the Indications for Vericiguat Approved by the Japanese Agency: From the KCHF Registry. Journal of Cardiac Failure 2023, 29(6), 976–978. [Google Scholar] [CrossRef] [PubMed]
  20. Boettcher, M.; Gerisch, M.; Lobmeyer, M.; Besche, N.; Thomas, D.; Gerrits, M.; Lemmen, J.; Mueck, W.; Radtke, M.; Becker, C. Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. Clin Pharmacokinet 2020, 59(11), 1407–1418. [Google Scholar] [CrossRef] [PubMed]
  21. Ruehs, H.; Klein, D.; Frei, M.; Grevel, J.; Austin, R.; Becker, C.; Roessig, L.; Pieske, B.; Garmann, D.; Meyer, M. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clin Pharmacokinet 2021, 60(11), 1407–1421. [Google Scholar] [CrossRef] [PubMed]
  22. Trujillo, M. E.; Arrington, L.; Patel, Y.; Passarell, J.; Wenning, L.; Blaustein, R. O.; Armstrong, P. W.; Meyer, M.; Becker, C.; Gheyas, F. Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. Clin Pharma and Therapeutics 2022, 112(5), 1061–1069. [Google Scholar] [CrossRef] [PubMed]
  23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf (accessed 2024-06-4).
  24. Australian Prescriber. New Drug: Vericiguat for Chronic Heart Failure. Aust Prescr 2023, 46 (4), 98–99. [CrossRef]
  25. Sharina, I.; Martin, E. Cellular Factors That Shape the Activity or Function of Nitric Oxide-Stimulated Soluble Guanylyl Cyclase. Cells 2023, 12(3), 471. [Google Scholar] [CrossRef] [PubMed]
  26. Yan, G.; You, B.; Chen, S.-P.; Liao, J. K.; Sun, J. Tumor Necrosis Factor-α Downregulates Endothelial Nitric Oxide Synthase mRNA Stability via Translation Elongation Factor 1-α 1. Circulation Research 2008, 103(6), 591–597. [Google Scholar] [CrossRef] [PubMed]
  27. Breitenstein, S.; Roessig, L.; Sandner, P.; Lewis, K. S. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. In Heart Failure; Bauersachs, J., Butler, J., Sandner, P., Eds.; Handbook of Experimental Pharmacology; Springer International Publishing: Cham, 2016; Vol. 243, pp 225–247. [CrossRef]
  28. Kemp-Harper, B.; Schmidt, H. H. H. W. cGMP in the Vasculature. In cGMP: Generators, Effectors and Therapeutic Implications; Schmidt, H. H. H. W., Hofmann, F., Stasch, J.-P., Eds.; Hofmann, F. B., Series Ed.; Handbook of Experimental Pharmacology; Springer Berlin Heidelberg: Berlin, Heidelberg, 2009; Vol. 191, pp 447–467. [CrossRef]
  29. Trujillo, M. E.; Ayalasomayajula, S.; Blaustein, R. O.; Gheyas, F. Vericiguat, a Novel sGC Stimulator: Mechanism of Action, Clinical, and Translational Science. Clinical Translational Sci 2023, 16(12), 2458–2466. [Google Scholar] [CrossRef] [PubMed]
  30. Lee, S.; Park, C. Y. Nitric Oxide: An Old Drug but with New Horizons in Ophthalmology—a Narrative Review. Ann Transl Med 2023, 11(10), 352. [Google Scholar] [CrossRef] [PubMed]
  31. Moncada, S. Nitric Oxide: Discovery and Impact on Clinical Medicine. J R Soc Med 1999, 92(4), 164–169. [Google Scholar] [CrossRef] [PubMed]
  32. Farah, C.; Michel, L. Y. M.; Balligand, J.-L. Nitric Oxide Signalling in Cardiovascular Health and Disease. Nat Rev Cardiol 2018, 15(5), 292–316. [Google Scholar] [CrossRef] [PubMed]
  33. Blanton, R. M. cGMP Signaling and Modulation in Heart Failure. Journal of Cardiovascular Pharmacology 2020, 75(5), 385–398. [Google Scholar] [CrossRef] [PubMed]
  34. Greene, S. J.; Gheorghiade, M.; Borlaug, B. A.; Pieske, B.; Vaduganathan, M.; Burnett, J. C.; Roessig, L.; Stasch, J.; Solomon, S. D.; Paulus, W. J.; Butler, J. The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. JAHA 2013, 2(6), e000536. [Google Scholar] [CrossRef] [PubMed]
  35. Busse, W. W.; Melén, E.; Menzies-Gow, A. N. Holy Grail: The Journey towards Disease Modification in Asthma. Eur Respir Rev 2022, 31(163), 210183. [Google Scholar] [CrossRef] [PubMed]
  36. Stasch, J.-P.; Evgenov, O. V. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. In Pharmacotherapy of Pulmonary Hypertension; Humbert, M., Evgenov, O. V., Stasch, J.-P., Eds.; Handbook of Experimental Pharmacology; Springer Berlin Heidelberg: Berlin, Heidelberg, 2013; Vol. 218, pp 279–313. [CrossRef]
  37. Böger, R. H. Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the “L-Arginine Paradox” and Acts as a Novel Cardiovascular Risk Factor. The Journal of Nutrition 2004, 134(10), 2842S–2847S. [Google Scholar] [CrossRef] [PubMed]
  38. Ahmad, A.; Dempsey, S.; Daneva, Z.; Azam, M.; Li, N.; Li, P.-L.; Ritter, J. Role of Nitric Oxide in the Cardiovascular and Renal Systems. IJMS 2018, 19(9), 2605. [Google Scholar] [CrossRef] [PubMed]
  39. Mangmool, S.; Duangrat, R.; Parichatikanond, W.; Kurose, H. New Therapeutics for Heart Failure: Focusing on cGMP Signaling. IJMS 2023, 24(16), 12866. [Google Scholar] [CrossRef]
  40. Vannuccini, F.; Campora, A.; Barilli, M.; Palazzuoli, A. Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications. Biomedicines 2022, 10(10), 2471. [Google Scholar] [CrossRef]
  41. Numata, G.; Takimoto, E. Cyclic GMP and PKG Signaling in Heart Failure. Front. Pharmacol. 2022, 13, 792798. [Google Scholar] [CrossRef] [PubMed]
  42. Dies, R. M.; Jackson, C. N.; Flanagan, C. J.; Sinnathamby, E. S.; Spillers, N. J.; Potharaju, P.; Singh, N.; Varrassi, G.; Ahmadzadeh, S.; Shekoohi, S.; Kaye, A. D. The Evolving Role of Vericiguat in Patients With Chronic Heart Failure. Cureus 2023. [CrossRef] [PubMed]
  43. Burnett John, C. Vericiguat — Another Victory for Targeting Cyclic GMP in Heart Failure. New England Journal of Medicine 2020, 382(20), 1952–1953. [Google Scholar] [CrossRef] [PubMed]
  44. Savarese, G. , Lindberg, F., Christodorescu, R. M., Ferrini, M., Kumler, T., Toutoutzas, K., Dattilo, G., Bayes-Genis, A., Moura, B., Amir, O., Petrie, M. C., Seferovic, P., Chioncel, O., Metra, M., Coats, A. J. S., & Rosano, G. M. C. (2024). Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. European Journal of Heart Failure, ejhf.3214. [CrossRef]
  45. Tamargo, J.; Kjeldsen, K. P.; Delpón, E.; Semb, A. G.; Cerbai, E.; Dobrev, D.; Savarese, G.; Sulzgruber, P.; Rosano, G.; Borghi, C.; Wassmann, S.; Torp-Pedersen, C. T.; Agewall, S.; Drexel, H.; Baumgartner, I.; Lewis, B.; Ceconi, C.; Kaski, J. C.; Niessner, A. Facing the Challenge of Polypharmacy When Prescribing for Older People with Cardiovascular Disease. A Review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy 2022, 8 (4), 406–419. [CrossRef]
  46. Kerwagen, F.; Ohlmeier, C.; Evers, T.; Herrmann, S.; Bayh, I.; Michel, A.; Kruppert, S.; Wilfer, J.; Wachter, R.; Böhm, M.; Störk, S. Real-World Characteristics and Use Patterns of Patients Treated with Vericiguat: A Nationwide Longitudinal Cohort Study in Germany. Eur J Clin Pharmacol 2024, 80(6), 931–940. [Google Scholar] [CrossRef] [PubMed]
  47. Adachi, T.; Iritani, N.; Kamiya, K.; Iwatsu, K.; Kamisaka, K.; Iida, Y.; Yamada, S. Prognostic Effects of Cardiac Rehabilitation in Patients with Heart Failure (from a Multicenter Prospective Cohort Study). The American Journal of Cardiology 2022, 164, 79–85. [Google Scholar] [CrossRef] [PubMed]
Preprints 110911 g001
Figure 1. Clinical progression of heart failure. Adapted from Bozkurt, 2024 [4].
Figure 1. Clinical progression of heart failure. Adapted from Bozkurt, 2024 [4].
Preprints 110911 g001
Preprints 110911 g003
Figure 3. Vericiguat.
Figure 3. Vericiguat.
Preprints 110911 g003
Preprints 110911 g004
Figure 4. Vericiguat metabolism.
Figure 4. Vericiguat metabolism.
Preprints 110911 g004
Preprints 110911 g005
Figure 5. NO synthesis. In living organisms, NO can be produced by L-arginine through the action of NO synthase (NOS) through consumption of reduced nicotinamide adenine dinucleotide phosphate (NADPH+) and oxygen that converts L-arginine to L-citrulline with NO production. NOS-independent NO formation can be interpreted as a contingency mechanism, ensuring adequate NO production in situations of limited oxygen supply.
Figure 5. NO synthesis. In living organisms, NO can be produced by L-arginine through the action of NO synthase (NOS) through consumption of reduced nicotinamide adenine dinucleotide phosphate (NADPH+) and oxygen that converts L-arginine to L-citrulline with NO production. NOS-independent NO formation can be interpreted as a contingency mechanism, ensuring adequate NO production in situations of limited oxygen supply.
Preprints 110911 g005
Preprints 110911 g006
Figure 6. Summary of the Mechanism of Action of Vericiguat. Nitric oxide (NO) is produced in the endothelium and diffuses into smooth muscle, where it binds to soluble guanylyl cyclase (sGC). This binding causes a conformational change that catalyzes the production of cyclic guanosine monophosphate (cGMP). The cGMP then activates downstream kinases, leading to vasodilation. Soluble guanylyl cyclase (sGC) stimulators and activators, including nitric oxide (NO), bind to the reduced heme (Fe2+) form of sGC. This interaction catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), resulting in vasodilation. Vericiguat directly stimulates sGC by binding to a specific site on its β-subunit.
Figure 6. Summary of the Mechanism of Action of Vericiguat. Nitric oxide (NO) is produced in the endothelium and diffuses into smooth muscle, where it binds to soluble guanylyl cyclase (sGC). This binding causes a conformational change that catalyzes the production of cyclic guanosine monophosphate (cGMP). The cGMP then activates downstream kinases, leading to vasodilation. Soluble guanylyl cyclase (sGC) stimulators and activators, including nitric oxide (NO), bind to the reduced heme (Fe2+) form of sGC. This interaction catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), resulting in vasodilation. Vericiguat directly stimulates sGC by binding to a specific site on its β-subunit.
Preprints 110911 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated